Affinia Therapeutics showcased preclinical data on AAV capsids targeting genetic cardiomyopathies and CNS diseases at the ASGCT 2024 Annual Meeting.

The company's novel capsids have increased specificity for cardiac and skeletal muscles and the CNS, and reduced targeting of the liver and DRG.

In non-human primates, their capsids demonstrated effective cardiac transduction and extensive brain distribution.

Affinia presented promising results for a BBB-penetrant AAV capsid in treating sporadic ALS, with significant neuronal transduction and Ataxin-2 gene reduction.

Their HEK-293 suspension cell manufacturing process yields high percentages of full capsids, suggesting quality and cost benefits for gene therapy production.

The leadership team's presence at the ASGCT 2024 Annual Meeting emphasizes their role as innovators in gene therapy.

Safety and efficacy data for a cardiotropic AAV capsid and a CNS tropic capsid discovery platform were also shared by Affinia.

Affinia Therapeutics is advancing gene therapy with a focus on rationally designed treatments that prioritize efficacy, safety, and manufacturability.